With Prevnar 20, Pfizer Aims To Maintain A Top Franchise

The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.

Number 20
Pfizer's Prevnar 20 was approved by FDA • Source: Alamy

Pfizer Inc.'s 20-valent pneumococcal vaccine Prevnar 20 was approved by the US Food and Drug Administration on 9 June, about one month ahead of an expected new pneumococcal vaccine from Merck & Co., Inc.. It’s an important approval for Pfizer’s life cycle management strategy as it attempts to maintain sales of its top-selling Prevnar franchise in the face of new competition.

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.